Fresenius SE & Co KGaA (FRA:FRE) has been given a €47.00 ($54.65) target price by research analysts at Jefferies Financial Group in a report issued on Friday. The firm presently has a “neutral” rating on the stock. Jefferies Financial Group’s price target would suggest a potential upside of 8.39% from the stock’s previous close.

Several other research firms have also issued reports on FRE. Sanford C. Bernstein set a €83.00 ($96.51) price target on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Monday, October 8th. Credit Suisse Group set a €58.00 ($67.44) price target on shares of Fresenius SE & Co KGaA and gave the company a “neutral” rating in a research report on Friday, December 7th. Kepler Capital Markets set a €65.00 ($75.58) price target on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Tuesday, November 20th. Warburg Research set a €65.00 ($75.58) price target on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Monday, December 10th. Finally, Berenberg Bank set a €81.85 ($95.17) price target on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Friday, November 23rd. Nine equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of €63.12 ($73.40).

FRA FRE opened at €43.36 ($50.42) on Friday. Fresenius SE & Co KGaA has a 12-month low of €60.16 ($69.95) and a 12-month high of €80.00 ($93.02).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Featured Article: How Do I Invest in Dividend Stocks

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.